Public Panel Offered on “Confronting the Confusion: How to Think About Breast Cancer Screening”
August 6, 2016

July 27, 2016, Portland OR – A free public forum about the science behind evolving breast cancer screening guidelines will be held August 6, 2016 from 2-5 PM at OHSU’s Collaborative Life Sciences Building.

This forum is the public portion of the 30th International Association for Breast Cancer Research Conference where leading breast cancer researchers from around the world will travel to Portland to focus on the biology and technology needed to enable earlier detection of lethal breast cancers.

This event is co-hosted by Susan G. Komen®, the OHSU Knight Cancer Institute, and the International Association for Breast Cancer Research. Welcoming and opening remarks will be made by Joe W. Gray, Ph.D., professor and Gordon Moore Endowed Chair of the Department of Biomedical Engineering at the OHSU Knight Cancer Institute, and Judith A. Salerno, M.D., M.S., CEO, Susan G. Komen.

The panel discussion will be moderated by Sue Best, M.S.W., L.C.S.W., Palliative Care Services and breast cancer survivor, OHSU. Panelists will include:

- **Toni Storm-Dickerson, M.D.**, Breast Surgical Oncologist, Compass Oncology
- **Pepper Schedin, Ph.D.**, Professor, Cell, Developmental & Cancer Biology; Co-Lead, Cancer Prevention and Control, Knight Cancer Institute, OHSU
- **Thea Tlsty, Ph.D.**, Professor of Pathology and Director of the Center for Translational Research in the Molecular Genetics of Cancer, UCSF; Director for the Program in Cell Cycling and Signaling, UCSF Helen Diller Family Comprehensive Cancer Center
- **Heidi Nelson, M.D., M.P.H.**, Medical Director of the Providence Women and Children’s Program and Research Center, and Research Professor in the Departments of Medical Informatics and Clinical Epidemiology and Medicine at OHSU
- June Cooley, breast cancer survivor and Scientific Research Advocate, Knight Cancer Institute, OHSU
• **Paul Spellman, Ph.D.**, Professor, Department of Molecular and Medical Genetics; Program Leader for Quantitative Oncology, Knight Cancer Institute, OHSU

• **Mark Kettler, M.D.**, Associate Professor, Department of Diagnostic Radiology, OHSU

After the forum, guests will have the opportunity to visit with top scientists during an interactive reception.

“Breast cancer screening recommendations are notoriously complicated for patients to navigate,” said Gray. “The panel of experts we’ve arranged to speak at this event are experts in their fields, and can provide clarity to attendees on the science behind current screening guidelines and recommendations. If you’re curious about when to get screened, and your personal risk factors, I’d encourage you to come to this event.”

Register at [Public Forum: Confronting the Confusion: How to think about breast cancer screening](#). The event location is at the Collaborative Life Sciences Building, 2730 SW Moody Ave. Portland, OR 97201.

**About Susan G. Komen Oregon and SW Washington**
In the last 25 years, the local organization has funneled nearly $19.8 million into programs that prioritize the importance of improving and building on the quality of life for survivors, emphasize the value of early detection and screenings, as well as financial assistance for access to treatment. Another $11.9 million has been dedicated to local cutting edge research.

**About the Knight Cancer Institute**
The [Knight Cancer Institute](#) at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute’s director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation’s top cancer centers. It is headquarters for one of the National Cancer Institute’s largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit [www.ohsu.edu/xd/health/services/cancer](http://www.ohsu.edu/xd/health/services/cancer) or follow us on [Facebook](#) and [Twitter](#).

Media contact:
Julie Dunn
Crusader Communications
[Julie@CrusaderCommunications.com](mailto:Julie@CrusaderCommunications.com)
503-720-6308